DEFM14A: Quanterix and Akoya Biosciences Announce Amended Merger Agreement and Shareholder Vote Details

Quanterix Corporation and Akoya Biosciences, Inc. have announced an amended merger agreement, where Akoya shareholders will receive a mix of Quanterix stock and cash, aiming to create a fully integrated technology ecosystem for biomarker detection.

Summary

• Quanterix Corporation (Quanterix) and Akoya Biosciences, Inc. (Akoya) have entered into an Amended and Restated Agreement and Plan of Merger, superseding their original January 9, 2025 agreement.
• Under the revised terms, each outstanding share of Akoya common stock will be converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash, without interest.
• The total stock consideration is capped at 19.99% of Quanterix's outstanding common stock immediately prior to the merger, and the total cash consideration is capped at $20 million, with adjustments to the exchange ratio and cash consideration if these limits are exceeded.
• Upon completion, current Quanterix stockholders are expected to own approximately 84.19% and former Akoya stockholders approximately 15.81% of the outstanding Quanterix common stock.
• The Akoya Board of Directors unanimously recommends that Akoya stockholders vote FOR the merger proposal at a special meeting scheduled for July 7, 2025.
• Akoya's unvested restricted stock units (RSUs) will convert into Quanterix RSUs, and outstanding Akoya options will vest and convert into cash and/or Quanterix stock based on a synthetic cashless exercise, or be cancelled if out-of-the-money.
• The merger is expected to close promptly following the Akoya Special Meeting, subject to Akoya stockholder approval, regulatory approvals (HSR Act waiting period already expired), and other closing conditions.
• Quanterix expects the combined company to generate approximately $55 million in total annual cost savings, accelerating its path to profitability and positive free cash flow in 2026.
• Akoya has disclosed substantial doubt about its ability to continue as a going concern if the merger is not consummated, due to recurring operating losses and non-compliance with certain debt covenants.
• Quanterix will provide Akoya with bridge financing of up to $30 million in convertible promissory notes, available for draw between June 15, 2025, and August 31, 2025 (if the merger is terminated), subordinated to Akoya's existing debt.

Sentiment

Score: 7

Explanation: The document presents a strategically positive outlook for the combined entity, emphasizing significant synergies and market expansion. However, it transparently discloses Akoya's severe standalone financial challenges and the complexities of the merger process, including activist shareholder opposition and prior renegotiations, which temper the overall positive sentiment.

Positives

• The merger creates the first fully integrated technology ecosystem to identify and measure biomarkers across tissue and blood, enhancing diagnostic relevance and accuracy.
• The combined entity will expand technology offerings into high-growth markets like oncology and immunology, capitalizing on a $5 billion serviceable addressable market.
• Leveraging Akoya's clinical partnerships and CLIA-certified lab services, Quanterix is strategically positioned to drive value creation in the rapidly emerging spatial biology clinical market.
• Significant cross-selling opportunities are expected due to complementary offerings and deep customer relationships, projecting strong double-digit organic revenue growth in 2026.
• The transaction is expected to generate approximately $55 million in total annual cost synergies by the end of 2026, with $20 million realized in the first year, accelerating the path to profitability and positive free cash flow in 2026.
• The combined company is expected to have over $297 million in cash as of March 31, 2025, providing financial flexibility to advance global diagnostic testing infrastructure.
• The revised merger terms no longer require Quanterix stockholder approval for the share issuance, reducing a significant closing condition risk.
• Akoya's financial advisor, Perella Weinberg Partners LP, opined that the Per Share Merger Consideration is fair, from a financial point of view, to Akoya stockholders.

Negatives

• The Per Share Merger Consideration reflects a substantially lower value to Akoya stockholders compared to the original merger agreement, and does not represent a premium over Akoya's trading price prior to the original announcement.
• The fixed Exchange Ratio will not adjust for changes in stock prices between signing and closing, meaning the value received by Akoya stockholders could be lower than implied at signing.
• Akoya's management anticipates some revenue dis-synergies as a result of the merger.
• Akoya stockholders will have a significantly lower ownership and voting interest (approximately 15.81%) in the combined company, reducing their influence.
• The combined company may face liquidity challenges in the next few years due to significant contingent liabilities and financial obligations.
• Akoya has incurred significant losses since inception and expects to continue incurring losses, raising substantial doubt about its ability to continue as a going concern if the merger is not consummated.
• If the merger is not completed, Akoya may be unable to meet its debt obligations, potentially leading to an event of default and acceleration of outstanding amounts under its existing loan documents.
• The merger agreement contains provisions that could discourage potential competing acquirers for Akoya, including a $2.6 million termination fee payable by Akoya under certain circumstances.

Risks

• The Exchange Ratio is fixed and will not be adjusted for changes in either Quanterix's or Akoya's stock price, leading to uncertainty in the value of consideration received by Akoya stockholders.
• The merger may not be completed due to failure to satisfy conditions, including Akoya stockholder approval, or termination of the Merger Agreement.
• The Merger Consideration is subject to limitations on the maximum aggregate number of Quanterix Common Stock shares issued (19.99%) and maximum aggregate cash ($20 million), which could lead to downward adjustments in per share value.
• The market price for Quanterix Common Stock may be affected by factors different from those that historically affected Akoya Common Stock, potentially leading to a decline in value for former Akoya stockholders.
• Actions of activist or dissident stockholders (e.g., Kent Lake, Tikvah Management) could delay or prevent the approval of the Merger and negatively affect Quanterix's and Akoya's business and operations.
• The Share Issuance may cause the market price of Quanterix Common Stock to decline due to dilution and potential sales by former Akoya stockholders.
• Combining the businesses of Quanterix and Akoya may be more difficult, costly, or time-consuming than expected, and the anticipated benefits and synergies may not be fully realized.
• The financial forecasts in the proxy statement are based on assumptions that may not be realized, and actual future results may vary materially.
• Akoya has incurred significant losses since inception and expects to incur future losses, raising substantial doubt about its ability to continue as a going concern if the merger is not consummated.
• Akoya's existing loan documents contain financial covenants that Akoya may be unable to meet, potentially requiring repayment of outstanding indebtedness in an event of default.
• Akoya is vulnerable to supply shortages and price fluctuations due to reliance on a limited number of third-party manufacturers and single-source suppliers.
• Changes in U.S. government policies, including reductions in federal research funding and increased tariffs, could adversely affect both Quanterix's and Akoya's businesses.
• Both companies face significant competition in the life sciences research and diagnostics markets, which could impact market acceptance and revenue.
• Defects or quality issues in products could lead to unforeseen costs, recalls, adverse regulatory actions, negative publicity, and litigation.
• Cybersecurity breaches, loss of data, and other disruptions could compromise sensitive information and expose the combined company to liability.
• Intellectual property protection may be inadequate, or infringement claims from third parties could be costly and time-consuming, affecting competitive advantage.
• The combined company's ability to attract, motivate, and retain key employees could be diminished due to merger uncertainty and integration challenges.
• Litigation related to the merger has been filed, and additional lawsuits may arise, potentially delaying the merger or impacting the combined company's business.

Future Outlook

Quanterix expects the combined company to achieve positive free cash flow in 2026, driven by anticipated annual cost synergies of approximately $55 million. Quanterix plans to launch its next-generation Simoa ONE instrument by the end of 2025, aiming for a 10-fold increase in sensitivity and expanded plexing. Additionally, Simoa ONE assay kits are expected to be compatible with over 20,000 existing flow cytometers worldwide via an early-access program in 2026, significantly expanding Quanterix's market reach. Akoya's growth strategy includes leveraging sales and marketing to drive adoption, investing in new applications and workflow improvements, forming analysis software partnerships, and investing in clinical developments to demonstrate validity, particularly in companion diagnostics.

Management Comments

• The Akoya Board unanimously recommends that Akoya stockholders vote FOR the Akoya Merger Proposal and FOR each of the other proposals to be considered at the Akoya Special Meeting.
• The Akoya Board determined that the Merger Agreement and the transactions contemplated by the Merger, are fair to, and in the best interests of, Akoya and its stockholders.
• Quanterix believes that the integration of Akoya's spatial biology capabilities in tissue with Quanterix's advanced tools for ultra-sensitive detection of biomarkers in blood will establish the first fully integrated technology ecosystem.
• Quanterix expects significant cross-selling opportunities to a combined 2,300 instrument install-base driving strong double-digit organic revenue growth in 2026.
• Quanterix's previous cost initiatives combined with the expected cost synergies from the transaction are expected to accelerate its path to profitability, including generating positive free cash flow in 2026.
• Akoya's management believes its platforms have potential applications across a wide range of markets and has targeted certain markets where its technology has significant advantages or a higher probability of success.

Industry Context

The merger aims to create a leading life sciences tools and diagnostics company by combining Quanterix's ultra-sensitive digital immunoassay platforms (Simoa technology for blood/fluid biomarker detection) with Akoya's spatial biology solutions (PhenoCycler and PhenoImager platforms for tissue analysis). This integration seeks to address the growing need for predictive biomarkers in areas like oncology, immunology, and neurology, enabling a paradigm shift towards earlier disease detection and personalized treatment. The spatial biology market is new and evolving, with significant growth expected, particularly in translational, clinical research, and routine clinical diagnostics. The combined entity seeks to leverage complementary offerings and deep customer relationships across discovery, translational, and clinical research to drive cross-selling and expand market presence.

Comparison to Industry Standards

• Quanterix's 2024 revenue growth of 12% outperformed the median 2024 revenue growth of its 2025 proxy peer group (NASDAQ Biotechnology Index), which was 2%, and outperformed all but one of its 2025 proxy peers in the life sciences tools and services segment.
• Quanterix's revenue growth was superior to that of certain larger companies in the life sciences tools and services segment, which had growth rates that were predominantly flat to declining.
• A 2024 Decibio report indicated that the spatial biology market is expected to grow 21% annually over the next 5 years, with translational and clinical research making up the largest segment and routine clinical diagnostics being the fastest growing, positioning Akoya's solutions favorably.
• A JAMA Oncology publication in 2019 established spatial phenotyping as superior for predicting patient response to immuno-therapies compared to NGS, RNA analysis, and standard diagnostic PD-L1 biomarker assays.
• A Nature publication in 2021 showed Akoya's spatial approach found topological differences in the tumor microenvironment, enabling correct patient stratification for immunotherapy where RNA-seq and other methods failed.
• The LucentAD p-Tau 217 test meets or exceeds the diagnostic performance criteria for a plasma-based test for Alzheimer's disease (90% accuracy, sensitivity, and specificity), as recommended by the Alzheimer's Association Workgroup.
• Quanterix's multi-marker algorithmic test (LucentAD Complete) delivered best-in-class performance for amyloid detection accuracy and reduced uncertainty in borderline cases across over 1,000 patients, compared to single-marker tests.

Management Changes

Corporate Governance

Legal Proceedings

• Two substantially similar complaints were filed by putative Akoya stockholders on April 22, 2025, and April 23, 2025, in the Supreme Court of New York, naming Akoya and its board members as defendants.
• These complaints allege negligent misrepresentation, concealment, and negligence, seeking injunctive relief to prevent the merger until additional disclosures are made, or rescission/damages if the merger is consummated.
• Akoya and Quanterix have each received demand letters alleging omission of material information in the Original Proxy Statement/Prospectus.
• The document notes the potential for additional demand letters or lawsuits against Akoya, Quanterix, and their respective boards in connection with the merger and proxy statement/prospectus.
• One of the conditions to the merger's completion is the absence of any final and non-appealable order or law prohibiting the merger, meaning successful litigation could prevent the transaction.

Related Party Transactions

• Quanterix has license agreements with Tufts University and Harvard University, from which a Quanterix Board member (Dr. David R. Walt) receives compensation based on royalties and license payments.
• Quanterix recorded approximately $2.1 million in royalty expense under the Tufts License Agreement in 2024.
• Quanterix recorded approximately $2.2 million in revenue from sales of products and services to laboratories affiliated with Harvard and Mass General Brigham (also affiliated with Dr. Walt) in 2024.
• Akoya has a relationship with Argonaut Manufacturing Services Inc. (AMS), a portfolio company of Telegraph Hill Partners, which holds more than 5% of Akoya's outstanding shares.
• Akoya incurred approximately $3.541 million in costs of goods sold related to consumables manufactured by AMS in 2024.
• Akoya had $581,000 in accounts payable due to AMS as of December 31, 2024.
• Akoya incurred research and development expenses of approximately $677,000 in 2024 with a software-as-a-service provider where one of Akoya's officers is a board member.

Stakeholder Impact

• **Shareholders (Akoya)**: Will receive a mix of Quanterix stock and cash, becoming Quanterix stockholders with a smaller ownership percentage (approx. 15.81%) in the combined entity. They face dilution and the risk that the value of the consideration may fluctuate. Appraisal rights are available for eligible stockholders.
• **Shareholders (Quanterix)**: Will experience dilution (approx. 15.81%) due to the issuance of new shares to Akoya stockholders. The merger is expected to enhance long-term value through strategic synergies and expanded market opportunities.
• **Employees (Akoya & Quanterix)**: Potential for job reductions (Quanterix announced a reduction-in-force of ~9M in headcount savings), but also opportunities within a larger, more diversified company. Retention of key employees is a focus, with severance benefits for Akoya executives in qualifying terminations.
• **Customers**: Expected to benefit from a broader and more integrated technology ecosystem for biomarker detection across tissue and blood, potentially leading to improved diagnostic tools and research capabilities.
• **Suppliers/Vendors**: Relationships may be impacted by the merger, with potential for renegotiated terms or changes in business relationships due to integration efforts and cost synergies.
• **Creditors (Akoya)**: Akoya's existing debt under the Midcap Trust Term Loan is expected to be repaid at closing, and Quanterix is providing bridge financing to address liquidity concerns if the merger is delayed or terminated.

Next Steps

• Akoya to hold a special meeting of its stockholders on July 7, 2025, to vote on the Akoya Merger Proposal and Akoya Adjournment Proposal.
• The merger is expected to close promptly following the Akoya Special Meeting, subject to satisfaction or waiver of closing conditions.
• Quanterix to file a post-effective amendment to the Form S-4 or a Form S-8 registration statement for shares issued in the merger no later than five days after the closing date.
• Akoya to cooperate with Quanterix to delist Akoya Common Stock from Nasdaq and deregister it under the Exchange Act as promptly as practicable after the Effective Time.
• Quanterix expects to launch its next-generation Simoa ONE instrument by the end of 2025.
• Quanterix expects to make its Simoa ONE assay kits compatible with over 20,000 existing flow cytometers worldwide through an early-access program in 2026.

Key Dates

Keywords

Merger, Acquisition, Quanterix Corporation, Akoya Biosciences, Life Sciences, Biomarkers, Spatial Biology, Diagnostics, Immunoassay, SEC Filing, Proxy Statement, Stockholder Vote, Nasdaq, QTRX, AKYA, Financial Performance, Synergies, Risk Factors, Corporate Governance, Capital Raise, Convertible Notes